Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells

Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling

(2016) Xin Xu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance

(2016) Shuai Wang et al.   MEDICAL SCIENCE MONITOR

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage

(2015) Takayo Fukuda et al.   CANCER SCIENCE

A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer

(2015) Bengt Gustavsson et al.   Clinical Colorectal Cancer

Epigenetic therapy as a novel approach in hepatocellular carcinoma

(2015) Ioannis Anestopoulos et al.   PHARMACOLOGY & THERAPEUTICS

Activin A induces growth arrest through a SMAD- dependent pathway in hepatic progenitor cells

(2014) Lin Chen et al.   Cell Communication and Signaling

Oxaliplatin-based Chemotherapy: A New Option in Advanced Hepatocellular Carcinoma. A Systematic Review and Pooled Analysis

(2014) F. Petrelli et al.   CLINICAL ONCOLOGY

Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer

(2014) Panagiotis A. Konstantinopoulos et al.   GYNECOLOGIC ONCOLOGY

Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma

(2014) Ze-yang Ding et al.   HEPATOLOGY

Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP

(2014) O. S. Chao et al.   MOLECULAR CANCER RESEARCH

Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin-induced Src activation in gastric cancer cells

(2014) CHENFEI ZHOU et al.   Molecular Medicine Reports

Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study

(2014) S. Qin et al.   ONCOLOGIST

Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights

(2014) Prithviraj Bose et al.   PHARMACOLOGY & THERAPEUTICS

Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

(2013) Shukui Qin et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer

(2012) Himashinie V.K. Diyabalanage et al.   CANCER LETTERS

Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway

(2012) Shuang Wei et al.   CARCINOGENESIS

HSCs play a distinct role in different phases of oval cell-mediated liver regeneration

(2012) Lin Chen et al.   CELL BIOCHEMISTRY AND FUNCTION

BRCA1-directed, enhanced and aberrant homologous recombination

(2012) Seth M. Dever et al.   CELL CYCLE

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial

(2012) Ann-Lii Cheng et al.   EUROPEAN JOURNAL OF CANCER

Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study

(2012) Aziz Zaanan et al.   JOURNAL OF HEPATOLOGY

Hepatocellular carcinoma

(2012) Alejandro Forner et al.   LANCET

Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma

(2011) Weijing Sun et al.   CANCER

The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells

(2011) Johanne I Weberpals et al.   Cancer Cell International

Oxaliplatin: a review in the era of molecularly targeted therapy

(2011) T. Alcindor et al.   Current Oncology

Management of hepatocellular carcinoma: An update

(2011) Jordi Bruix et al.   HEPATOLOGY

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Management of advanced hepatocellular carcinoma in the era of targeted therapy

(2010) Thomas Yau et al.   LIVER INTERNATIONAL

Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion

(2010) Pei-Jer Chen et al.   LIVER INTERNATIONAL

Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor

(2010) Sushant K. Kachhap et al.   PLoS One

The role of BRCA1 in DNA damage response

(2010) Jiaxue Wu et al.   Protein & Cell

HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines

(2009) Sylwia Flis et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer

(2009) M. G. Fakih et al.   CLINICAL CANCER RESEARCH

Rational Combinations Using HDAC Inhibitors

(2009) M. Bots et al.   CLINICAL CANCER RESEARCH

Antimetastatic Role of Smad4 Signaling in Colorectal Cancer

(2009) Bixiang Zhang et al.   GASTROENTEROLOGY

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009

(2009) Donald Poon et al.   LANCET ONCOLOGY

Inhibition of transcription by platinum antitumor compounds

(2009) Ryan C. Todd et al.   Metallomics

Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs

(2008) Kei-ichi Ozaki et al.   CANCER SCIENCE

Histone deacetylase inhibitors in cancer therapy

(2008) Min-Jung Lee et al.   CURRENT OPINION IN ONCOLOGY

Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay

(2008) Jin C. Kim et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systemic Chemotherapy of Hepatocellular Carcinoma – Korean Experience

(2008) Han Chu Lee   ONCOLOGY